Patents by Inventor M. SEAN BAILEY

M. SEAN BAILEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 9139654
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: September 22, 2015
    Assignee: Roche GlyeArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey, M. Sean Bailey
  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 9068005
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: June 30, 2015
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 8629248
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: January 14, 2014
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 8623644
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: January 7, 2014
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey
  • Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
    Patent number: 8021856
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: September 20, 2011
    Assignee: Roche GlycArt AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey, M. Sean Bailey, legal representative
  • Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
    Publication number: 20110142825
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Application
    Filed: May 28, 2010
    Publication date: June 16, 2011
    Applicant: ROCHE GLYCART AG
    Inventors: PABLO UMAÑA, JOËL JEAN-MAIRET, JAMES E. BAILEY, M. SEAN BAILEY
  • Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
    Patent number: 7517670
    Abstract: The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: April 14, 2009
    Assignee: GlycArt Biotechnology AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, M. Sean Bailey, legal representative, James E Bailey